Advanced search
Publication Cover
International Reviews of Immunology Volume 21, 2002 - Issue 1
Submit an article Journal homepage
31
Views
13
CrossRef citations to date
0
Altmetric
Research Article

Anti-β 2 -Glycoprotein I Autoantibodies and Atherosclerosis

EIJI MATSUURA Department of Cell Chemistry and Department of Medicine III, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan
,
KAZUKO KOBAYASHI Department of Cell Chemistry and Department of Medicine III, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan
,
JUNKO KASAHARA Department of Cell Chemistry and Department of Medicine III, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan
,
TATSUJI YASUDA Department of Cell Chemistry and Department of Medicine III, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan
,
HIROFUMI MAKINO Department of Cell Chemistry and Department of Medicine III, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan
,
TAKAO KOIKE Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan
&
YEHUDA SHOENFELD Department of Medicine B, The Research Unit of Autoimmune Diseases, Chaim Sheba Medical Center, Tel Hashomer, Israel
 show all
Pages 51-66 | Published online: 03 Aug 2009

  • M.L. Boey, C.B. Colaco, A.E. Gharavi, K.B. Elkon, S. Loizou and G.R. V. Hughes, Thrombosis in systemic lupus erythematosus: Striking association with the presence of circulation lupus anticoagulant. Br. Med. J., 287: 1021-1023, 1983.
  • E.N. Harris, A.E. Gharavi, M.L. Boey, B.M. Patel, C.G. Mackworth-Young, S. Loizou and G.R. V. Hughes, Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet, 2: 1211-1214, 1983.
  • G.R. V. Hughes, E.N. Harris and A.E. Gharavi, The anticardiolipin syndrome. J. Rheumatol., 13: 486-489, 1986.
  • M. Galli, P. Comfurius, C. Maassen, H.C. Hemker, M.H. de Baets, P.J. C. van BredaVriesman, T. Barbui, R.F. A. Zwaal and E.M. Bevers, Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet, 335: 1544-1547, 1990.
  • H.P. McNeil, R.J. Simpson, C.N. Chesterman and S.A. Krilis, Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: ß2-glycoprotein I (apolipoprotein H). Proc. Natl. Acad. Sci. USA, 87: 4120-4124, 1990.
  • E. Matsuura, Y. Igarashi, M. Fujimoto, K. Ichikawa and T. Koike, Anticardiolipin cofactorts) and differential diagnosis of autoimmune disease. Lancet, 336: 177-178, 1990.
  • A. Tsutsumi, E. Matsuura, K. Ichikawa, A. Fujisaku, M. Mukai, S. Kobayashi and T. Koike, Antibodies to ß2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum., 39: 1466-1474, 1996.
  • D. Alarcon-Segovia and A.R. Cabrai, The concept and classification of antiphospholipid/cofactor syndromes. Lupus, 5: 364-367, 1996.
  • E. Matsuura, Y. Igarashi, T. Yasuda, D.A. Triplett and T. Koike, Anticardiolipin antibodies recognize ß2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J. Exp. Med., 179: 457-462, 1994.
  • M.S. Brown and J.L. Goldstein, The hyperlipoproteinemias and other disorders of lipid metabolism. Harrison's Principles of Internal Medicine, 13th edition. In: K.D. Isselbacher, ed. New York: McGraw-Hill, Inc. 2058-2069, 1994.
  • J.L. Witztum and D. Steinberg, Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88: 1785-1792, 1991.
  • J.L. Goldstein, Y.K. Ho, S.K. Basu and M.S. Brown, Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl. Acad. Sci., USA, 76: 333-337, 1979.
  • K.D. O'Brien, C.E. Alpers, J.E. Hokanson, S. Wang and A. Chait, Oxidation-specific epitopes in human coronary atherosclerosis are not limited to oxidized low-density lipoprotein. Circulation, 94: 1216-1225, 1996.
  • O. Vaarala, G. Alfthan, M. Jauhiainen, M. Leirisalo-Repo, K. Aho and T. Palosuo, Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet, 341: 923-925, 1993.
  • F.J. Tinahones, M.J. Cuadrado, M.A. Khamashta, F. Mujic, J.M. Gomez-Zumaquero, E. Collantes and G.R. V. Hughes, Lack of cross-reaction between antibodies to ß2-glycoprotein-I and oxidized low-density lipoprotein in patients with antiphospholipid syndrome. Br. J. Rheumatol., 37: 746-749, 1998.
  • F.I. Romero, O. Amengual, T. Atsumi, M.A. Khamashta, F.J. Tinahones and G.R. V. Hughes, Arterial disease in lupus and secondary antiphospholipid syndrome: Association with anti-ß2glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein. Br. J. Rheumatol., 37: 883-888, 1998.
  • Y. Hasunuma, E. Matsuura, Z. Makita, T. Katahira, S. Nishi and T. Koike, Involvement of ß22-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin. Exp. Immunol., 107: 569-573, 1997.
  • S. HU+00F6rkko, E. Miller, E. Dudl, P. Reaven, L.K. Curtiss, N.J. Zvaifler, R. Terkeltaub, S.S. Pierangeli, D.W. Branch, W. Palinski and J.L. Witztum, Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes on oxidized low-density lipoprotein. J. Clin. Invest., 98: 815-825, 1996.
  • S. Hörkko, E. Miller, D.W. Branch, W. Palinski and J.L. Witztum, The epitopes for some antiphospholipid antibodies are adducts of oxidized phospholipid and ß2 glycoprotein 1 (and other proteins). Proc. Natl. Acad. Sci. USA, 94: 10356-10361, 1997.
  • S. Hörrko, D.A. Bird, E. Miller, H. Itabe, N. Leitinger, G. Subbanagounder, J.A. Berliner, P. Friedman, E.A. Dennis, L.K. Curtiss, W. Palinski and J.L. Witztum, Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J. Clin. Invest., 103: 117-128, 1999.
  • A.D. Watson, N. Leitinger, M. Navab, K.F. Faull, S. Hörkko, J.L. Witztum, W. Palinski, D. Schwenke, R.G. Salomon, W. Sha, G. Subbanagounder, A.M. Fogelman and J.A. Berliner, Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J. Biol. Chem., 272: 13597-13607, 1997.
  • K. Kobayashi, E. Matsuura, Q. Liu, J. Furukawa, K. Kaihara, J. Inagaki, T. Asumi, N. Sakairi, T. Yasuda, D.V. Voelker and T. Koike, A specific ligand for ß2-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages, J. Lipid Res., 42: 697-709, 2001.
  • J. Frostegard, R. Wu, A. Haegerstrand, M. Patarroyo, A.K. Lefvert and J. Nilsson, Mononuclear leukocytes exposed to oxidized low density lipoprotein secrete a factor that stimulates endothelial cells to express adhesion molecules. Atherosclerosis, 103: 213-219, 1993.
  • S.D. Gushing, J.A. Berliner, A.J. Valente, M.C. Territo, M. Navab, F. Parhami, R. Gerrity, C.J. Schwartz and A.M. Fogelman, Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc. Natl. Acad. Sci. USA, 87: 5134-5138, 1990.
  • T.B. Rajavashisth, A. Andalibi, M.C. Territo, J.A. Berliner, M. Navab, A.M. Fogelman and A.J. Lusis, Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature, 344: 254-257, 1990.
  • A. Nakata, J. Miyagawa, S. Yamashita, M. Nishida, R. Tamura, K. Yamamori, T. Nakamura, S. Nozaki, K. Kameda-Takemura, S. Kawata, N. Taniguchi, S Higashiyama and Y. Matsuzawa, Localization of heparin-binding epidermal growth factor-like growth factor in human coronary arteries. Possible roles of HB-EGF in the formation of coronary atherosclerosis. Circulation, 94: 2778-2786, 1996.
  • N. Watanabe, M. Kurabayashi, Y. Shimomura, K. Kawai-Kowase, Y. Hoshino, I. Manabe, M. Watanabe, M. Aikawa, M. Kuro-o, T. Suzuki, Y. Yazaki and R. Nagai, BTEB2 Nagai, a Kruppel-like transcription factor, regulates expression of the SMemb/nonmuscle myosin heavy chain B (SMemb/NMHC-B) gene. Cric. Res., 85: 182-191, 1999.
  • F.S. Santiago, H.C. Lowe, M.M. Kavurma, C.N. Chesterman, A. Baker, D.G. Atkins and L.M. Khachigian, New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nature Med., 5: 1438, 1999.
  • F. Mach, U. Schonbeck, G.K. Sukhova, E. Atkinson and P. Libby, Reduction of athrosclerosis in mice by inhibition of CD40 signalling. Nature, 394: 200-203, 1998.
  • W. Jessup, Oxidized lipoproteins and nitric oxide. Curr. Opin. Lipidol., 7: 274-280, 1996.
  • D. Steinberg, Low density lipoprotein oxidation and its pathobiological significance. J. Biol. Chem., 272: 20963-20966, 1997.
  • L.G. Fong, S. Parthasarathy, J.L. Witztum and D. Steinberg, Nonenzymatic oxidative cleavage of peptide bonds in apoprotein B-100. J. Lipid Res., 28: 1466-1477, 1987.
  • H. Esterbauer, G. Jurgens, O. Quehenberger and E. Koller, Autoxidation of human low density lipoprotein: Loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. J. Lipid Res., 28: 495-509, 1987.
  • L. Nagy, P. Tontonoz, J.G. Alvarez, H. Chen and R.M. Evans, Oxidized LDL regulates macrophage gene expression through ligand activation of PPARy. Cell 93: 229-240, 1998.
  • A. Weidtmann, R. Scheithe, N. Hrboticky, A. Pietsch, R. Lorenz and W. Siess, Mildly oxidized LDL induces platelet aggregation through activation of phospholipase A2. Arterioscler. Thromb. Vase. Biol., 15: 1131-1138, 1995.
  • L. Kritharides, W. Jessup, J. Gifford and R.T. Dean, A method for defining the stages of low density lipoprotein oxidation by the separation of cholesterol- and cholesteryl ester-oxidation products using HPLC. Anal. Biochem., 213: 79-89, 1993.
  • M. van Heek, D. Schmitt, P. Toren, M.K. Cathcart and P.E. DiCorleto, Cholesteryl hydroperoxyoctadecadienoate from oxidized low density lipoprotein inactivated platelet-derived growth factor. J. Biol. Chem., 273: 19405-19410, 1998.
  • A.J. Brown, S.L. Leong, R.T. Dean and W. Jessup, 7-Hydroperoxycholesterol and its products in oxidized low density lipoprotein and human atherosclerotic plaque. J. Lipid Res., 38: 1730-1745, 1997.
  • A.J. Brown and W. Jessup, Oxysterols and atherosclerosis. Atherosclerosis, 142: 1-28, 1999.
  • H. Kamido, A. Kuksis, L. Marai and J.J. Myher, Identification of cholesterol-bound aldehydes in copper-oxidized low density lipoprotein. FEBS Lett., 304: 269-272, 1992.
  • H. Kamido, A. Kuksis, L. Marai and J.J. Myher, Lipid ester-bound aldehydes among copper-catalyzed peroxidation products of human plasma lipoproteins. J. Lipid Res., 36: 1876-1886, 1995.
  • G. Hoppe, A. Ravandi, D. Herrera, A. Kuksis and H.F. Hoff, Oxidation products of cholesteryl linoleate are resistant to hydrolysis in macrophages, form complexes with proteins, and are present in human atherosclerotic lesions. J. Lipid Res., 38: 1347-1360, 1997.
  • H.A. Kleinveld, H.L. M. Hak-Lemmers, A.F. H. Stalenhoef and P.N. M. Demacker, Improved measurement of low-density-lipoprotein susceptibility to copper-induced oxidation: Application of a short procedure for isolating low-density lipoprotein. Clin. Chem., 38: 2066-2072, 1992.
  • S. Parthasarathy, L.G. Fong, M.T. Quinn and D. Steinberg, Oxidative modification of LDL: Comparison between cell-mediated and copper-mediated modification. Ear. Heart J., 11: (Suppl.) E: 83-87, 1990.
  • S. Yla-Herttuala, W. Palinski, M.E. Rosenfeld, S. Parthasarathy, TE. Carew, S. Butler, J.L. Witztum and D. Steinberg, Evidence for presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Invest., 85: 1086-1095, 1989.
  • E. Ehrenwald, G.M. Chisolm and RL. Fox, Intact ceruloplasmin oxidatively modifies low density lipoprotein. J. Clin. Invest., 93: 1493-1501, 1994.
  • D. Lamb and D.S. Leake, Acidic pH enables caeruloplasmin to catalyse the modification of low-density lipoprotein. FEBS Lett., 338: 122-126, 1994.
  • H.E. Schultze, K. Heide and H. Haupt, Uber ein bisher ubekanntes niedermolekulare ß2globulin des humanserums. Naturwissenschaften, 48: 719-724, 1961.
  • H. Wurm, ß2-glycoprotein I (apolipoprotein H) interactions with phospholipid vesicles. Int. J. Biochem., 16: 511-515, 1984.
  • E. Polz, Isolation of a specific lipid-binding protein from human serum by affinity chromatography using heparin-Sepharose. In: H. Peelers, ed., Properties of biological fluids. Pergamon: Oxford Press, 817-820, 1979.
  • E. Polz and G.M. Kostner, The binding of ß2glycoprotein I to human serum lipoproteins: Distribution among density fraction. FEBS lett., 102: 183-186, 1979.
  • J. Nimpf, E.M. Bevers, RH. Bomans, U. Till, H. Wurm, G.M. Kostner and R.F. Zwaal, Prothrombinase activity of human platelets is inhibited by ß2-glycoprotein I. Biochim. Biophys. Acta, 884: 142-149, 1986.
  • I. Schousboe, ß2-Glycoprotein I: A plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood, 66: 1086-1091, 1985.
  • J. Nimpf, H. Wrum and G.M. Kostner, ß2-Glycoprotein I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis, 63: 109-114, 1987.
  • M. Ieko, K. Ichikawa, D.A. Triplett, E. Matsuura, T. Atsumi, K. Sawada and T. Koike, ß2-Glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. Arthritis Rheum., 42: 167-174, 1999.
  • E. Matsuura, Y. Igarashi, T. Yasuda, D.A. Triplett and T. Koike, Anticardiolipin antibodies recognize ß2glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J. Exp. Med., 179: 457-462, 1994.
  • D. Steinberg, Low density lipoprotein oxidation and its pathobiological significance. J. Biol. Chem., 272: 20963-20966, 1997.
  • K. Nishikawa, H. Arai and K. Inoue, Scavenger receptor-mediated uptake and metabolism of lipid vesicles containing acidic phospholipids by mouse peritoneal macrophages. J. Biol. Chem., 265: 5226-5231, 1990.
  • R.L. Griffith, G.T. Virella, H.C. Stevenson and M.F. Lopes-Virella, Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes; a possible mechanism of foam cell formation. J. Exp. Med., 168: 1041-1059, 1988.
  • M.F. Lopes-Virella, N. Binzafar, S. Rackley, A. Takei, M. La Via and G. Virella, The uptake of LDL-IC by human macrophages: Predominant involvement of the FcyRI receptor. Atherosclerosis, 135: 161-170, 1997.
  • J.C. Khoo, E. Miller, F. Pio, D. Steinberg and J.L. Witztum, Monoclonal antibodies against LDL further enhance macrophage uptake of LDL aggregates. Arterioscler. Thromb., 12: 1258-1266, 1992.
  • P.A. Kiener, B.M. Rankin, P.M. Davis, S.A. Yocum, G.A. Warr and R.I. Grove, Immune complexes of LDL induce atherogenic responses in human monocytic cells. Arterioscler. Thromb. Vase. Biol., 15: 990-999, 1995.
  • P.M. Morganelli, R.A. Rogers, T.J. Kitzmiller and A. Bergeron, Enhanced metabolism of LDL aggregates mediated by specific human monocyte IgG Fc receptors. J. Lipid Res., 36: 714-724, 1995.
  • J.E. Hunt and S.A. Krilis, The fifth domain of ß2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. J. Immunol., 152: 653-659, 1994.
  • B. Bouma, RG. de Groot, J.M. H. van den Elsen, R.B. G. Ravelli, A. Scheuten, M.J. A. Simmelink, R.H. W.M. Derksen, J. Kroon and R Gros, Adhension mechanism of human ß2-glycoprotein I to phospholipids based on its crystal structure. EMBO J., 18: 5166-5174, 1999.
  • M. Igarashi, E. Matsuura, Y. Igarashi, H. Nagae, K. Ichikawa, D.A. Triplett and T. Koike, Human ß2-glycoprotein I as an anticardiolipin cofactor determined using deleted mutants expressed by a baculovirus system. Blood, 87: 3262-3270, 1996.
  • G.M. Iverson, E.J. Victoria and D.M. Marquis, Anti-ß2-glycoprotein I (ß2GPI) autoantibodies recognize an epitope on the first domain of ß2GPI. Proc. Natl. Acad. Sci., USA, 95: 15542-15546, 1998.
  • W. Palinski, M.E. Rosenfeld, S. Yla-Herttuala, G.C. Gumer, S.S. Socher, S.W. Butler, S. Parathasarathy, T.E. Carew, D. Steinberg and J.L. Witztum, Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci., USA, 86: 1372-1376, 1989.
  • W. Palinski, S. Yla-Harttuala, M.E. Rosenfeld, S.W. Butler, S.A. Socher, S. Parathasarathy, L.K. Curtiss and J.L. Witztum, Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Atherosderosis, 10: 325-335, 1990.
  • J.T. Salonen, S. Yla-Herttuala, R. Yamamoto, S. Butler, H. Korpela, R. Salonen, K. Nyyssonen, W. Palinski and J.L. Witztum, Autoantibody against oxidized LDL and progression of carotide atherosclerosis. Lancet, 339: 883-887, 1992.
  • M. Puurunen, O. Vaarala, H. Julkunen, K. Aho and T. Palosuo, Antibodies to phospholipid binding proteins and occurrence of thrombosis in patients with systemic lupus erythematosus. Clin. Immunol. Immunopathol., 80: 16-22, 1996.
  • J. George, A. Afek, B. Gilburd, M. Blank, Y. Levy, A. Aron-Maor, H. Levkovitz, A. Shaish, I. Goldberg, J. Kopolovic, D. Harats and Y. Shoenfeld, Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with ß2-glycoprotein I, Circulation, 98: 1108-1115, 1988.
  • J. George, D. Harats, B. Gilburd, A. Afek, Y. Levy, J. Schneiderman, I. Barshack, J. Kopolovic and Y. Shoenfeld, Immunolocalization of ß2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: Potential implications for lesion progression. Circulation, 9: 2227-2230, 1999.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.